Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | GPR139 | Q6DWJ6 | 3/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1846931 | 0.81 | CMA1 (0.41) | CMA1 | |
| SCHEMBL1847168 | 0.72 | GAA (0.49) | CMA1GPR139HTTMAPTKMT2A | |
| SCHEMBL15141744 | 0.66 | GPR84 (0.46) | MAPTKMT2AGPR84 | |
| SCHEMBL1851878 | 0.66 | CMA1 (0.44) | CMA1HTTMAPTKMT2A | |
| SCHEMBL6115321 | 0.64 | PARG (0.35) | CMA1GPR139HTTMAPTKMT2A | |
| SCHEMBL18887413 | 0.64 | GPR139 (0.35) | CMA1GPR139HTTMAPTKMT2A | |
| SCHEMBL2696996 | 0.64 | CMA1 (0.55) | CMA1 | |
| SCHEMBL2695531 | 0.63 | CMA1 (0.45) | CMA1MAPTKMT2A | |
| SCHEMBL2696231 | 0.63 | CMA1 (0.43) | CMA1MAPTKMT2A | |
| SCHEMBL2695228 | 0.62 | CMA1 (0.55) | CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969348-B2 | Chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| US-20120129863-A1 | CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| EP-2323991-A2 | CHYMASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129863-A1 | CHYMASE INHIBITORS | CMA1, CPA3, SERPINB1 | CMA1 1/4885GPR139 2064/4885HTT 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.